Contact
Menu
About us
Impacting the future
History
Careers
Strategies
Human Health
Formation
Ventures
Growth
Planetary Health
BioEconomy
Portfolio
Ventures
Growth
BioEconomy
Team
Sustainability
Human Health
Responsible investment
Impact on human health
SFDR
Planetary Health
Responsible investment
Impact on planetary health
SFDR
News & Insights
News
Insights
Events
Media resources
Contact
Investor portal
Linkedin
YouTube
X
About us
Impacting the future
History
Careers
Strategies
Human Health
Planetary Health
Portfolio
Ventures
Growth
BioEconomy
Team
Sustainability
Human Health
Planetary Health
News & Insights
News
Insights
Events
Media resources
Portfolio
ARMGO Pharma
Portfolio
ARMGO Pharma
Portfolio
ARMGO is a venture-backed biotech company developing Rycals®, novel small molecule drugs that target the ryanodine receptor calcium ion channels (RyR).
Human Health
armgo.com
Industry
Biotech
Status
Past
Forbion team
Geert-Jan Mulder
MD
Managing Partner
Dmitrij Hristodorov
PhD
General Partner
Subscribe
Yes, I give permission to store and process my data
Submit